

**Silicon Laboratories Inc.**  
**Condensed Consolidated Statements of Operations**  
(In thousands, except per share data)  
(Unaudited)

	<b>Three Months Ended</b>	
	<b>March 30, 2024</b>	<b>April 1, 2023</b>
Revenues	\$ 106,375	\$ 246,787
Cost of revenues	51,306	92,927
Gross profit	55,069	153,860
Operating expenses:		
Research and development	80,650	89,396
Selling, general and administrative	33,553	44,891
Operating expenses	114,203	134,287
Operating income (loss)	(59,134)	19,573
Other income (expense):		
Interest income and other, net	2,732	4,836
Interest expense	(509)	(1,656)
Income (loss) before income taxes	(56,911)	22,753
Provision (benefit) for income taxes	(385)	7,753
Equity-method loss	—	(1,033)
Net income (loss)	<u>\$ (56,526)</u>	<u>\$ 13,967</u>
Earnings (loss) per share:		
Basic	\$ (1.77)	\$ 0.44
Diluted	\$ (1.77)	\$ 0.41
Weighted-average common shares outstanding:		
Basic	31,910	31,959
Diluted	31,910	33,753

**Silicon Laboratories Inc.**  
**Condensed Consolidated Balance Sheets**  
(In thousands, except per share data)  
(Unaudited)

	<u>March 30, 2024</u>	<u>December 30, 2023</u>
<b>Assets</b>		
Current assets:		
Cash and cash equivalents	\$ 191,489	\$ 227,504
Short-term investments	141,201	211,720
Accounts receivable, net	32,616	29,295
Inventories	198,206	194,295
Prepaid expenses and other current assets	82,608	75,117
Total current assets	<u>646,120</u>	<u>737,931</u>
Property and equipment, net	142,155	145,890
Goodwill	376,389	376,389
Other intangible assets, net	53,453	59,533
Other assets, net	126,036	123,313
Total assets	<u>\$ 1,344,153</u>	<u>\$ 1,443,056</u>
<b>Liabilities and Stockholders' Equity</b>		
Current liabilities:		
Accounts payable	\$ 44,575	\$ 57,498
Revolving line of credit	—	45,000
Deferred revenue and returns liability	3,921	2,117
Other current liabilities	62,863	58,955
Total current liabilities	<u>111,359</u>	<u>163,570</u>
Other non-current liabilities	67,233	70,804
Total liabilities	<u>178,592</u>	<u>234,374</u>
Commitments and contingencies		
Stockholders' equity:		
Preferred stock – \$0.0001 par value; 10,000 shares authorized; no shares issued	—	—
Common stock – \$0.0001 par value; 250,000 shares authorized; 31,924 and 31,897 shares issued and outstanding at March 30, 2024 and December 30, 2023, respectively	3	3
Additional paid-in capital	29,830	16,973
Retained earnings	1,136,205	1,192,731
Accumulated other comprehensive loss	(477)	(1,025)
Total stockholders' equity	<u>1,165,561</u>	<u>1,208,682</u>
Total liabilities and stockholders' equity	<u>\$ 1,344,153</u>	<u>\$ 1,443,056</u>

**Silicon Laboratories Inc.**  
**Condensed Consolidated Statements of Cash Flows**  
(In thousands)  
(Unaudited)

	<b>Three Months Ended</b>	
	<b>March 30, 2024</b>	<b>April 1, 2023</b>
<b>Operating Activities</b>		
Net income (loss)	\$ (56,526)	\$ 13,967
Adjustments to reconcile net income to net cash used in operating activities:		
Depreciation of property and equipment	6,634	6,235
Amortization of other intangible assets	6,079	6,510
Amortization of debt issuance costs	—	523
Stock-based compensation expense	13,612	16,638
Equity-method loss	—	1,033
Deferred income taxes	(5,270)	(2,670)
Changes in operating assets and liabilities:		
Accounts receivable	(3,321)	(16,257)
Inventories	(3,958)	(32,794)
Prepaid expenses and other assets	(15,466)	11,530
Accounts payable	(13,829)	(12,966)
Other current liabilities and income taxes	1,554	(8,529)
Deferred revenue and returns liability	1,804	4,478
Other non-current liabilities	(3,113)	(978)
Net cash used in operating activities	<u>(71,800)</u>	<u>(13,280)</u>
<b>Investing Activities</b>		
Purchases of marketable securities	(9,794)	(66,113)
Sales of marketable securities	25,763	170,317
Maturities of marketable securities	55,188	157,734
Purchases of property and equipment	(2,047)	(7,657)
Proceeds from sale of equity investment	12,382	—
Net cash provided by investing activities	<u>81,492</u>	<u>254,281</u>
<b>Financing Activities</b>		
Payments on debt	(45,000)	—
Repurchases of common stock	—	(17,608)
Payment of taxes withheld for vested stock awards	(1,048)	(6,931)
Proceeds from the issuance of common stock	341	—
Net cash used in financing activities	<u>(45,707)</u>	<u>(24,539)</u>
Increase (decrease) in cash and cash equivalents	(36,015)	216,462
Cash and cash equivalents at beginning of period	227,504	499,915
Cash and cash equivalents at end of period	<u>\$ 191,489</u>	<u>\$ 716,377</u>

## Non-GAAP Financial Measurements

In addition to the GAAP results provided throughout this document, Silicon Labs has provided non-GAAP financial measurements on a basis excluding non-cash and other charges and benefits. Details of these excluded items are presented in the tables below, which reconcile the GAAP results to non-GAAP financial measurements.

The non-GAAP financial measurements do not replace the presentation of Silicon Labs' GAAP financial results. These measurements provide supplemental information to assist management and investors in analyzing Silicon Labs' financial position and results of operations. Silicon Labs has chosen to provide this information to investors to enable them to perform meaningful comparisons of past, present and future operating results and as a means to emphasize the results of core on-going operations.

### Unaudited Reconciliation of GAAP to Non-GAAP Financial Measures (In thousands, except per share data)

Non-GAAP Income Statement Items	Three Months Ended March 30, 2024						
	GAAP Measure	GAAP Percent of Revenue	Stock Compensation Expense	Intangible Asset Amortization	Termination Costs	Non-GAAP Measure	Non-GAAP Percent of Revenue
Revenues	\$ 106,375						
Gross profit	55,069	51.8 %	\$ 412	\$ —	\$ —	\$ 55,481	52.2 %
Research and development	80,650	75.8 %	9,722	6,061	407	64,460	60.6 %
Selling, general and administrative	33,553	31.5 %	3,477	19	156	29,901	28.1 %
Operating expenses	114,203	107.4 %	13,199	6,080	563	94,361	88.7 %
Operating income (loss)	(59,134)	(55.6)%	13,611	6,080	563	\$ (38,880)	(36.5)%

Non-GAAP Loss Per Share and Income Tax Rate	Three Months Ended March 30, 2024							Non-GAAP Tax Percentage Rate
	GAAP Measure	GAAP Tax Percentage Rate	Stock Compensation Expense	Intangible Asset Amortization	Termination Costs	Income Tax Adjustments	Non-GAAP Measure	
Income (loss) before income taxes	\$ (56,911)		\$ 13,611	\$ 6,080	\$ 563	\$ —	\$ (36,657)	
Benefit for income taxes	(385)	0.7 %				(6,946)	(7,331)	20.0 %
Net loss	\$ (56,526)						\$ (29,326)	
Diluted shares outstanding	31,910						31,910	
Diluted loss per share	\$ (1.77)						\$ (0.92)	

**Unaudited Forward-Looking Statements Regarding Business Outlook\*\***  
(In millions, except per share data)

<b>Business Outlook</b>	<b>Three Months Ended June 29, 2024</b>		
	<b>GAAP Measure</b>	<b>Non-GAAP Adjustments*</b>	<b>Non-GAAP Measure</b>
Gross margin	53%	0%	53%
Operating expenses	\$ 125	\$ (23)	\$ 102
Diluted loss per share - low	\$ (1.61)	\$ 0.91	\$ (0.70)
Diluted loss per share - high	\$ (1.45)	\$ 0.87	\$ (0.58)

\* Non-GAAP adjustments include the following estimates: stock compensation expense of \$16.0 million, intangible asset amortization of \$6.1 million, termination costs of \$1.3 million, and the application of a long-term non-GAAP tax rate of 20%.

\*\* These financial schedules contain forward-looking statements based on Silicon Labs' current expectations. The words "believe," "estimate," "expect," "intend," "anticipate," "plan," "project," "will" and similar phrases as they relate to Silicon Labs are intended to identify such forward-looking statements. These forward-looking statements reflect the current views and assumptions of Silicon Labs and are subject to various risks and uncertainties that could cause actual results to differ materially from expectations. Among the factors that could cause actual results to differ materially from those in the forward-looking statements are the following: the competitive and cyclical nature of the semiconductor industry; the challenging macroeconomic environment including disruptions in the financial services industry; geographic concentration of manufacturers, assemblers, test service providers and customers in Asia that subjects Silicon Labs' business and results of operations to risks of natural disasters, epidemics or pandemics, war and political unrest; risks that demand and the supply chain may be adversely affected by military conflict (including in the Middle East, and between Russia and Ukraine), terrorism, sanctions or other geopolitical events globally (including in the Middle East, and conflict between Taiwan and China); risks that Silicon Labs may not be able to maintain its historical growth; quarterly fluctuations in revenues and operating results; difficulties developing new products that achieve market acceptance; risks associated with international activities (including trade barriers, particularly with respect to China); intellectual property litigation risks; risks associated with acquisitions and divestitures; product liability risks; difficulties managing and/or obtaining sufficient supply from Silicon Labs' distributors, manufacturers and subcontractors; dependence on a limited number of products; absence of long-term commitments from customers; inventory-related risks; difficulties managing international activities; risks that Silicon Labs may not be able to manage strains associated with its growth; credit risks associated with its accounts receivable; dependence on key personnel; stock price volatility; the impact of COVID-19 on the U.S. and global economy; debt-related risks; capital-raising risks; the timing and scope of share repurchases and/or dividends; average selling prices of products may decrease significantly and rapidly; information technology risks; cyber-attacks against Silicon Labs' products and its networks; risks associated with any material weakness in our internal controls over financial reporting; and other factors that are detailed in the SEC filings of Silicon Laboratories Inc. Silicon Labs disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. References in these financial schedules to Silicon Labs shall mean Silicon Laboratories Inc.